Enliven Therapeutics Showcases Research at the AACR Annual Meeting
Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ: ELVN), a clinical-stage biopharmaceutical firm focused on discovering and developing small molecule therapeutics, has announced a significant participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting. This event is set to be a platform for recent advancements in cancer research with presentations scheduled throughout the event.
Poster Presentation Highlights
Enliven is set to present five distinct posters that demonstrate their innovative approach to oncology. Each presentation highlights advanced research efforts aimed at improving patient outcomes in cancer treatment.
ELVN-002: A Novel HER2 Inhibitor
The first poster, designated Abstract 4712, focuses on ELVN-002, a potent and selective HER2 inhibitor. This drug exhibits a unique binding mode, which may enhance its efficacy when combined with HER2-targeting antibody-drug conjugates. This presentation is scheduled for April 29 at 9:00 a.m. CDT, in Poster Section 34, within the session concerning Targeted Therapies and Combinations 2.
Mechanistic PKPD Model for CML
Another session, highlighted by Abstract 4361, will delve into the development of a pharmacokinetic pharmacodynamic (PKPD) model aimed at predicting the effects of tyrosine kinase inhibitors on chronic myeloid leukemia (CML). Set to occur on April 29 at 9:00 a.m. CDT in Poster Section 20, this poster represents a systematic approach to addressing therapeutic predictability.
ELV-3111: Enhancing Anti-Tumor Activity
Abstract LB295 highlights ELV-3111, a type 1 pan-RAF inhibitor. This therapeutic demonstrates promising capacity when combined with MEK inhibitors, particularly for NRAS and BRAF mutant cancers. This session will take place on April 29 at 9:00 a.m. CDT in Poster Section 52, under Late-Breaking Research.
Mechanism of Selective Inhibition of RAF
In addition, the presentation listed under Abstract LB294 discusses the mechanisms by which a Type 1 RAF inhibitor selectively inhibits dimeric RAF. Scheduled for the same time and location as the previous poster, this presentation underscores the company's commitment to unraveling complex molecular interactions.
ELVN-001: Targeting ABL1 Kinase
Lastly, Enliven will present Abstract 5515, which focuses on ELVN-001, a highly selective ATP-competitive ABL1 tyrosine kinase inhibitor. This treatment option aims to address chronic myeloid leukemia both independently and in combination with the therapeutic asciminib. This presentation is set for April 29 at 2:00 p.m. CDT, in Poster Section 17, delving into drug resistance challenges within targeted therapies.
Access to Research and Findings
For those interested in the abstracts, they will be accessible on the AACR website. Following the presentations, copies of these insights and findings will also be available under the Program Presentations & Publications section of Enliven’s official website. This continued dissemination of knowledge reinforces the company's commitment to transparency and scientific progress.
About Enliven Therapeutics
Enliven Therapeutics is dedicated to the discovery and development of innovative small molecule therapeutics aimed at improving the quality of life for patients. The company’s mission centers on addressing unmet medical needs through a precision oncology approach, maximizing survival rates and quality of life for those affected by cancer.
Frequently Asked Questions
1. What is the AACR Annual Meeting?
The AACR Annual Meeting is a major event showcasing the latest cancer research and advancements in cancer therapeutics, bringing together experts from around the world.
2. How many posters will Enliven Therapeutics present?
Enliven Therapeutics will present a total of five posters at the meeting, each covering various aspects of cancer research and therapeutic efficacy.
3. What are the focus areas of Enliven’s research presentations?
The focus areas include targeted therapies for HER2 inhibition, pharmacokinetics in cancer, pan-RAF inhibition, and selective inhibition of ABL1 kinase, among others.
4. Where can I find the research abstracts?
The abstracts will be available on the AACR website, and later, on Enliven Therapeutics’ website under the relevant publications section.
5. What is the mission of Enliven Therapeutics?
Enliven Therapeutics strives to improve cancer treatment outcomes through the development of innovative therapies that address unmet medical needs in oncology.
